Article

Dual-functional Nanocarrier for Improved Immunochemotherapy of Acute Myeloid Leukemia

2026-06-18

Abstract excerpt

<title>Abstract</title> <p>Advances with the 7 + 3 regimen and liposomal CPX-351 have significantly improved the treatment of acute myeloid leukemia (AML); however, challenges like drug resistance and immune evasion persist. Despite the demonstrated potential of immunotherapy in treating several types of solid tumors, its impact on the treatment of AML remains limited. To address these challenges, we engineered a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 74fe33cd-43b4-52c5-b679-c4640a3b61cb
DOI: 10.21203/rs.3.rs-9901177/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dual-functional Nanocarrier for Improved Immunochemotherapy of Acute Myeloid LeukemiaDOI 10.21203/rs.3.rs-9901177/v1Read

Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance.Semantic proximity Read

CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.Semantic proximity Read

RNA-loaded nanoparticles for the treatment of hematological cancersSemantic proximity Read

The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and SafetySemantic proximity Read

Current trends in molecular diagnostics of chronic myeloid leukemiaSemantic proximity Read

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AMLSemantic proximity Read

In-depth comparative characterization identifies scalable CD123-CAR-NK cells as promising strategy to combat AMLSemantic proximity Read

CLL1 polymeric nanoparticles loaded with PI3K/BRD4 dual inhibitor MDP5 and azacitidine as a novel treatment for TP53 mutated acute myeloid leukemia.Semantic proximity Read

A Modular Layer-by-Layer Nanoparticle Platform for Hematopoietic Progenitor and Stem Cell TargetingSemantic proximity Read

Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialSemantic proximity Read

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.Semantic proximity Read

TriLeukeVax: A CD80/IL-15/IL-15Rα Expressing Autologous AML Cell Vaccine Elicits Robust Anti-Leukemic Cytolytic ActivitySemantic proximity Read